Table 2.

Multivariate Analyses of MEIS-Positive vs. MEIS-Negative Tumors

	Risk of Biochemical Recurrence			Risk of Clinical Metastasis
	HR	95% CI	P-Value	HR	95% CI	P-Value
MEIS Percent
<5%	Ref	Ref	Ref	Ref	Ref	Ref
>5%	0.76	(0.43 – 1.37)	0.37	0.28	(0.08 – 0.90)	0.03
Age	1.02	(0.99 – 1.05)	0.18	0.98	(0.95 – 1.02)	0.39
Race
White	Ref	Ref	Ref	Ref	Ref	Ref
Other	0.68	(0.25 –1.81)	0.44	0.29	(0.07 – 1.27)	0.10
PSA	1.00	(0.99 – 1.02)	0.66	0.99	(0.97 – 1.01)	0.43
Gleason Grade
5–6	Ref	Ref	Ref	Ref	Ref	Ref
3+4 or 4+3	1.28	(0.76 – 2.17)	0.35	1.51	(0.66 – 3.46)	0.33
8–10	1.57	(0.89 – 2.74)	0.12	2.58	(1.09 – 6.12)	0.03
Clinical T Stage
T1	Ref	Ref	Ref	Ref	Ref	Ref
T2	1.17	(0.70 – 1.95)	0.56	2.42	(0.96 – 6.09)	0.06
T3–4	1.08	(0.50 – 2.34)	0.85	2.95	(0.94 – 9.22)	0.06
Pathological Extension
Organ Confined	Ref	Ref	Ref	Ref	Ref	Ref
Extra-Prostatic Extension	1.21	(0.62 – 2.39)	0.58	0.99	(0.37 – 2.70)	0.99
Seminal Vesicle Invasion	1.45	(0.65 – 3.25)	0.37	2.20	(0.76 – 6.38)	0.15
Lymph Node Positive	1.84	(0.87 – 3.90)	0.11	2.62	(0.95 – 7.20)	0.06
Surgical Margins
T1	Ref	Ref	Ref	Ref	Ref	Ref
T2	1.18	(0.81 – 1.71)	0.40	0.75	(0.45 – 1.25)	0.26